Navigation Links
Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
Date:2/17/2011

TARRYTOWN, N.Y., Feb. 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the full year and fourth quarter of 2010 and provided an update on development programs and upcoming milestones.  

"2010 was a very productive year for Regeneron as we reported positive Phase 3 results in four clinical trials: two with VEGF Trap-Eye in wet age-related macular degeneration, called wet AMD, one with VEGF Trap-Eye in central retinal vein occlusion, and one with ARCALYST® for the prevention of gout flares in patients initiating uric-acid lowering therapy," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  "We expect regulatory applications to be filed in the first half of 2011 for marketing approval in the U.S. and Europe for VEGF Trap-Eye in wet AMD.  We also look forward to reporting results from additional Phase 3 trials in central retinal vein occlusion and gout and from two Phase 3 trials with aflibercept in cancer."

"In anticipation of potential product approvals," Dr. Schleifer added, "we are continuing to build our commercialization capabilities.  We are also advancing our earlier-stage pipeline which currently includes eight fully-human monoclonal antibodies in clinical development for the treatment of various diseases and conditions including elevated LDL cholesterol, rheumatoid arthritis, atopic dermatitis, and cancer.  We anticipate Phase 2 data from some of these programs in 2011."

"We entered 2011 in a strong financial position to support our development and commercialization activities," commented Murray A. Goldberg, Chief Financial Officer, "with approximately $627 million in cash and securities, following a successful public offering of Common Stock in October 2010."

Clinical Programs UpdateVEGF Trap-Eye (aflibercept opht
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Mass. , July 24, 2014   ndd ... function testing (PFT) employing precise ultrasound technology, announced that ... the instrument to measure Carbon Monoxide Diffusing Capacity (DLCO) ... the most comprehensive study of Chronic Obstructive Pulmonary Disease ... cause of death in the U.S. and affects millions ...
(Date:7/23/2014)... N.Y. , July 23, 2014 ... of idelalisib to treat patients with relapsed chronic ... lymphocytic lymphoma (SLL) is a significant advance for ... Idelalisib, which goes by the trade name Zydelig®, ... protein that is highly expressed in many B-cell ...
(Date:7/23/2014)... MOUNTAIN VIEW, Calif. , July 23, 2014 ... translational preclinical research, today unveiled their new logo and ... transformation of Surpass, corporate culture to one where our ... This press release comes on the heels of the ... to the Silicon Valley Team:  David Craig, a veteran ...
Breaking Medicine Technology:EasyOne Pro from ndd Medical Technologies Chosen Again as the Exclusive PFT Testing Technology in Phase 2 of COPDGene Study 2The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3
... Feb. 15 Intra-Cellular Therapies, Inc. (ITI),announced ... its,first-in-class dual 5HT2A receptor antagonist/dopamine receptor,phosphoprotein modulator ... ITI,s family of compounds that inhibit a ... dysfunction in schizophrenia. Data,characterizing the pharmacological profile ...
... Plan Also Calls for Expansion of Business Development, Streamlining of ... ... Conference Call/Webcast at 11 a.m. EST Today -, LA JOLLA, Calif., ... strategic plan for 2008 with a focus,on clinical development activities to maximize ...
Cached Medicine Technology:Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders 2Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders 3Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders 4TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 2TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 3TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 4TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 5TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 6
(Date:7/24/2014)... July 24, 2014 A new report ... nearly 80 percent of doctors in the U.S. have upgraded ... year. , Doctors appear to be embracing more digital options. ... time, linking them to past patient histories, the latest published ... physician. , A report from the Robert Wood Johnson ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Representatives from ... be on hand to provide educational and support resources ... Meeting next week in Colorado Springs. , The Annual ... of the most renowned neurointerventional research centers ... and innovating together (with or at) symposiums, physician meetings, ...
(Date:7/24/2014)... The Arm Lift, also known as brachioplasty, is ... from the upper arms to create a more toned, slimmed ... can become lax and may begin to sag, resulting in ... appearance of sagging upper arms, and seek treatment to restore ... is now offering brachioplasty to tighten and improve the contours ...
(Date:7/24/2014)... Colo. (PRWEB) July 24, 2014 ... Prepared to Identify and Prevent the Three Infections ... Infections?’ is a go-to guide to help ... risk factors and details basic prevention measures that ... The e-book is available for download at ...
(Date:7/24/2014)... 24, 2014 The Republic of Tea, leading ... CARDAMOM CRÈME BRÛLÉE TEA to celebrate “The Hundred-Foot Journey,” a ... and Juliet Blake. A hundred-foot journey begins in the moment ... into a new realm that is far out of your ... physical distance that materially changes the course of your life ...
Breaking Medicine News(10 mins):Health News:Doctors Embracing Changing Technologies, And Technology Brings Options to Treatment 2Health News:Doctors Embracing Changing Technologies, And Technology Brings Options to Treatment 3Health News:Brain Aneurysm Foundation Provides Key Support to NeuroIntervential Physicians 2Health News:How to Get Toned Arms With Arm Lift Procedure 2Health News:How to Get Toned Arms With Arm Lift Procedure 3Health News:New E-book Helps Nurses Identify and Prevent Three Most Common Healthcare Associated Infections 2Health News:New E-book Helps Nurses Identify and Prevent Three Most Common Healthcare Associated Infections 3Health News:The Republic of Tea Unveils New Tea Inspired by “The Hundred-Foot Journey” 2Health News:The Republic of Tea Unveils New Tea Inspired by “The Hundred-Foot Journey” 3
... , WEDNESDAY, Dec. 8 (HealthDay News) -- ... of developing several invasive bacterial diseases, according to a ... found to be especially strong for children 6 years ... the risk for invasive meningococcal disease, the analysis found, ...
... 8, 2010) Jeffrey S. Upperman, MD, director of ... a call to action for filling a significant gap in ... the framework for a pediatric applied trauma research network (PATRN). ... Journal of Pediatric Surgery and the Journal ...
... breakthrough? See what the experts have to say ... Perspectives on Psychological Science . Neuroimaging: ... Special Section on fMRI ( http://pps.sagepub.com/content/5/6/714.full ) ... widespread interest following the publication of Vul et ...
... , WEDNESDAY, Dec. 8 (HealthDay News) -- The children ... pregnancy are less likely to develop atopic dermatitis in their ... Atopic dermatitis (also called atopic eczema) is a chronic and ... The condition affects up to 20 percent of children in ...
... , WEDNESDAY, Dec. 8 (HealthDay News) -- A new ... blood to scan the genome of a fetus may offer ... genetic diseases, a new study suggests. Currently, a sample ... amniocentesis or chorionic villus sampling, both of which pose a ...
... ANN ARBOR, Mich. Patients who have complications after ... even when it is clearly recommended for their diagnosis, ... Cancer Center finds. In addition, patients with complications ... chemotherapy delayed for more than 120 days after diagnosis ...
Cached Medicine News:Health News:Trauma surgeon leads call to action for pediatric applied trauma research network 2Health News:fMRI special section of Perspectives on Psychological Science 2Health News:fMRI special section of Perspectives on Psychological Science 3Health News:Surgery complications linked to chemotherapy delay, U-M study finds 2
Long-Sleeve Bolero for targeted compression in the upper arms, upper back and shoulder areas. Plush-shielded hook and eye front closure for comfort and convenient application....
Velcro® closure, uniform contour compression, available as 9" and 12" bands for abdominal support, 9" can be used as a breast wrap....
Sub Pectoral Breast Augmentation Wrap...
CDIs Ultra-Comfort Bra™ is designed with special single needle stitching that places the cup seams away from critical surgical sites....
Medicine Products: